Thinking about switching from compounded to brand-name?
Brand-name Zepbound and Wegovy are now similarly priced to compounded tirzepatide or semaglutide for most patients — with the safety, dosing consistency, and regulatory clarity that only FDA-approved medication provides.
No payment required to start. Direct-pay only — no insurance billing.
Why patients are switching
The compounded GLP-1 market grew rapidly during the 2023–2024 semaglutide shortage. With brand supply restored and FDA enforcement increasing, the calculus has changed.
Brand pricing has dropped dramatically
LillyDirect now offers Zepbound at $299/mo for starter doses — matching what compounders charge for compounded tirzepatide. Wegovy via NovoCare Pharmacy runs $199–399/mo. The gap between compounded and brand has narrowed or closed for most patients.
FDA enforcement is tightening
The FDA has issued multiple warning letters to compounded GLP-1 providers in 2025 and 2026, including dosing errors, fraudulent labels, and unapproved chemical forms. Several large compounded GLP-1 telehealth companies have received FDA warning letters about misleading marketing. The regulatory window that let compounded semaglutide and tirzepatide flourish during the 2023–2024 shortage is closing.
Supply reliability
If your compounding pharmacy stops making your medication — whether from FDA pressure, supply-chain issues, or business changes — you could face a gap in treatment mid-titration. Brand-name medication comes from the manufacturer's own supply chain with none of that risk.
Dosing consistency and safety testing
Brand-name medication is FDA-approved with verified dosing, sterility, and manufacturing standards. Compounded versions vary in potency and quality — the FDA has specifically flagged dosing errors and contamination in compounded GLP-1 products.
How brand pricing compares
Direct-pay manufacturer pricing for the FDA-approved options we prescribe, versus typical compounded rates.
| Medication | Format | Direct-pay (manufacturer) |
|---|---|---|
| Zepbound (tirzepatide) | Weekly injection | $299–$499/mo (LillyDirect) |
| Wegovy (semaglutide) | Weekly injection | $199–$399/mo (NovoCare) |
| Typical compounded (for comparison) | Varies | $179–$499/mo |
Pricing varies by dose. Valitide charges a flat $99/mo subscription on top of the medication cost.
How the transition works
Complete our 5-minute intake
Tell us your current medication, dose, and history. No insurance information required — we route every prescription direct-pay.
Provider review within 24-48 hours
A licensed nurse practitioner or physician in your state reviews your intake and determines the best brand-name option given your dose, side-effect history, and preferences.
Prescription routes to your chosen pharmacy
Your provider sends the prescription to LillyDirect (Zepbound) or NovoCare Pharmacy (Wegovy) for shipment, or to a local pharmacy you choose for pickup. Either way, no insurance billing or PA waits.
Medication ready in 3–5 business days
LillyDirect and NovoCare Pharmacy both ship cold-chain directly to your door. If you chose a local pharmacy, you'll get a notification when it's ready for pickup.
Common questions about switching
Can I switch mid-dose, or do I have to start over?
In most cases you can transition at or near your current dose without restarting titration — your provider will review your current regimen and recommend the best bridge. Switching between tirzepatide products (compounded tirzepatide to Zepbound) is usually most seamless. Switching classes (tirzepatide to semaglutide, or vice versa) may require some re-titration to manage side effects.
Does Valitide bill insurance for this?
No. Valitide is built for direct-pay access. We route every prescription to the manufacturer's pharmacy at the manufacturer's published self-pay rate. We don't bill insurance and we don't handle prior authorizations. If you have insurance coverage for GLP-1s and want to use it, a full-service telehealth platform is a better fit.
How does brand-name pricing compare to what I'm paying for compounded?
For most patients on compounded tirzepatide ($179–499/mo), Zepbound via LillyDirect at $299–499/mo is in the same range. For semaglutide patients, Wegovy via NovoCare ($199–399/mo) is competitive with most compounded semaglutide pricing. The exact comparison depends on your dose.
Is there any risk in switching?
Brand-name medications have the same or stronger clinical evidence than compounded versions — the active ingredients are identical, and brand-name undergoes rigorous FDA safety testing. The main adjustment is typically minor: dose timing, injection technique (if switching from vial to pen), or tolerating the different inactive ingredients. Your provider manages this transition.
How long does the transition take?
From intake to your first brand-name shipment: typically 3–7 days. If you're running low on your compounded supply, let your provider know and they'll expedite.
Can I stay on compounded and use Valitide for provider care?
Valitide prescribes only FDA-approved brand-name medications. We don't write compounded prescriptions. If you want to continue on a compounded regimen, you'd need to stay with your existing compounded provider.
Ready to make the switch?
Start with our 5-minute eligibility check. Ships from LillyDirect or NovoCare Pharmacy — or routes to a local pharmacy you choose.
Check Eligibility